Equity
€2.4m ▲ 74.2%
Equity rose in 2025 from €1.4m to €2.4m.
EVENS OCULAR ASSOCIATES
Lifetime
19 annual accounts with figures on one time axis, 24 filings since 2002Gross marginpeak €2.9m (2024)
€2.6m▼ 9.9%
Resultpeak €1.2m (2024)
€624,401▼ 49.0%
Equitypeak €2.4m (2025)
€2.4m▲ 74.2%
Debts
€1.3m▼ 50.0%
Staffpeak 16.4 FTE (2025)
16.4 FTE▲ 15.5%
Board2 names since 2019
2 directorsAl SABAI Nashwan and 1 other
Owners
50%EYEFIX
Documentsfilings and deeds
02-02-20262 days late
2025abbreviated format
Result from €1.2m to €624,401Staff from 14.2 FTE to 16.4 FTEEquity from €1.4m to €2.4mDebts from €2.6m to €1.3mCash from €507,107 to €895,867
Key points
from the 2025 annual accountsInvestments
€7,388 0.1 × depreciation
Green is investment, beige is depreciation.
Staff
16 employees on 30-06-2025
In 2025, 7 people joined and 7 left.
Liquidity
3.50 was 1.16 in 2024
Short-term debts fell from €1.8m to €530,936.
Filings
24 annual accounts since 2002
Seven of the last ten came late. The 2021 accounts came latest: 56 days after the end of the period.
Position in the sector
€624,401
Higher net result than 92% of companies in human health. Sector median €110,314 · 3,006 companies.
Checked score
97
Excellent
Financially stronger than 73% of small companies in human health (NACE 86)
Probability in this band: under 0.55%
Bankruptcy probability within 12 months
< 0.1% Very low
0%0.5%1.5%4%10%≥ 25%
The dashed line is the sector median: < 0.1% across 1,081 companies (NACE 86, small).
Fewer than 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
12-2024: 0.1%
01-2025: 0.1%● unchanged vs 12-2024
02-2025: 0.1%● unchanged vs 01-2025
03-2025: < 0.1%▼ -0.1 percentage points vs 02-2025
04-2025: < 0.1%● unchanged vs 03-2025
05-2025: < 0.1%● unchanged vs 04-2025
06-2025: < 0.1%● unchanged vs 05-2025
07-2025: < 0.1%● unchanged vs 06-2025
08-2025: < 0.1%● unchanged vs 07-2025
09-2025: < 0.1%● unchanged vs 08-2025
10-2025: < 0.1%● unchanged vs 09-2025
11-2025: < 0.1%● unchanged vs 10-2025
12-2025: 0.1%▲ +0.1 percentage points vs 11-2025
01-2026: 0.1%● unchanged vs 12-2025
02-2026: 0.2%▲ +0.1 percentage points vs 01-2026highest value
03-2026: < 0.1%▼ -0.2 percentage points vs 02-2026lowest value
04-2026: < 0.1%● unchanged vs 03-2026lowest value
05-2026: < 0.1%● unchanged vs 04-2026lowest value
06-2026: < 0.1%● unchanged vs 05-2026lowest value
07-2026: < 0.1%● unchanged vs 06-2026lowest value
08-2026: < 0.1%● unchanged vs 07-2026lowest value
09-2026: < 0.1%● unchanged vs 08-2026
10-2026: < 0.1%● unchanged vs 09-2026
11-2026: < 0.1%● unchanged vs 10-2026
Financial strengthStrong
Score breakdown
lowers risk
Liquidity: current ratio 3.50, cash €895,867
Sector: Human health activities (NACE 86)
Equity €2.4m (64.7% of total assets)
Profit of €624,401 (financial year 2025)
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 86, small). It does better than 42% of them on solvency, 71% on liquidity, 81% on profitability and 97% on growth.
The bankruptcy probability was computed on 05-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
The probability rests on the annual accounts with balance sheet date 30-06-2025.
Of the companies with a bankruptcy probability in the very low class on 30-06-2025, 0.1% went bankrupt within twelve months.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Comparable companies, two years later
In July 2024, 20,136 companies had the same profile as EVENS OCULAR ASSOCIATES has now. Each dot stands for 51 companies, two years later.
95.0%
were still trading
4.7%
stopped another way
0.2%
went bankrupt
That fits the bankruptcy probability of EVENS OCULAR ASSOCIATES itself: < 0.1% within 12 months.
Test of the method
The method was tested on the 497,446 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 20,136 companies, not a prediction for EVENS OCULAR ASSOCIATES. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit of up to €220,000 on 30-day terms is acceptable
Liquidity is ample, with a current ratio of 3.5 (1.16 in 2024), above the usual 1.5. Short-term debt is 14.6% and cash 24.6% of total assets. 35.3% of the assets are financed with debt and provisions.
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Five signals.
lowers riskraises risk
raises risk · 2025 accounts filed 2 days late
The financial year that closed on 30-06-2025 was due by 31-01-2026 and was filed on 02-02-2026, 2 days later. Nearly half (47%) of Belgian companies file late; of those that file 1 to 90 days late, 2.0% are now bankrupt, dissolved or in another special legal status, against 1.66% of all filers. A delay like this does not count in the score.
NBB · 10 filingsDeviation from the deadline
2025
2 days late
2024
26 days late
2023
35 days early
2022
22 days late
2021
56 days late
2020
24 days late
2019
24 days late
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
The company filed its last 7 accounts on average 17 days after the deadline. In the sector (NACE 86), the median for financial year 2024 was 7 days before the deadline, and 36% of those companies filed late.
Searched, nothing found (2)
neutral · Next filing not due yet
The financial year that closed on 30-06-2026 is due by 31-01-2027. Nothing is late today. The company usually files around 22 February (4 of the last 5 accounts filed within 34 days either side of that date).
Companies Code · seven monthsWhere today falls in the filing period
30-06-2026 year end06-11-2026 today31-01-2027 deadline
Board and ownership
AS
Al SABAI Nashwan
Director, since 25-06-2019
PB
PION Bart
Director, since 25-06-2019
- BPAL 100%equity €2.2m (2025) · 30-06-2025 annual accounts of BPAL
- EYEFIX 50%score 98equity €10.5m (2025) · 2025 annual accounts of EYEFIX
Recent changes
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0473645654
Demerger proposal: EVENS OCULAR ASSOCIATES splits off to FOCUS IMMO
Appointment: Bart Roobrouck (company auditor) · Gazette deed
Environmental permit refused
Verbouwen en/of uitbreiden met functiewijziging en met wijziging van aantal woongelegenheden · Wemmel
First establishment
Focus Eye Clinic, Kaasmarkt 131, Wemmel
Comparable companies
same main activity, similar in size and age| Company | Total assets | Gross margin | Solvency | Staff |
|---|---|---|---|---|
| EVENS OCULAR ASSOCIATES Wemmel | €3.6m | €2.6m | 64.7% | 16.4 |
| BELGO-INTERNATIONAL RESEARCH APPLICATIONS en DEVELOPMENT Genk | €3.0m | €2.4m | 9.0% | 22.3 |
| OOGINSTITUUT Aalst | €2.4m | €2.8m | 71.4% | 11.8 |
| ClinChoice Belgium Kraainem | €2.6m | €1.8m | 6.9% | 20.5 |
| Beclinic Overijse | €4.9m | €1.9m | 68.2% | 9.9 |
| Diagnosecentrum Noord-Limburg Lommel | €6.6m | €2.8m | 77.0% | 25.5 |
| Maison médicale Saint Léonard Centre de Santé intégré asbl Liège | €1.9m | €2.0m | 70.2% | 22.6 |
These companies have the same main activity as EVENS OCULAR ASSOCIATES: specialist medical practice (NACE 86220). They are comparable in size and age: total assets between €1.9m and €6.6m, founded between 1993 and 2008.
Official details
Source: KBO- Status
- Active since 29-12-2000Normal situation
- Activity
- Specialist medical practiceNACE 86220
- Joint committee
- 330Health institutions and services · annual accounts 30-06-2025
- Establishment unit
- 2.230.434.3311780 Wemmel, since 26-09-2011
- Financial year end
- 30 June
- Peppol
- Reachable since 27-10-2026
Annual accounts to 30-06-2025
- Turnover
- ≈ €2.3mestimated
- Total assets
- €3.6m▼ 7.2%
- Employeeson 30-06-2025
- 16=
- Filing
- Filed on 02-02-2026
Insights on EVENS OCULAR ASSOCIATES
EVENS OCULAR ASSOCIATES files the abbreviated format. That format states no turnover. The gross margin rose from €234,433 in 2007 to €2.6m in 2025.
The balance sheet grew most from 2019 to 2021 through fixed assets.
BPAL holds all the shares.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about EVENS OCULAR ASSOCIATES
- What is the company number of EVENS OCULAR ASSOCIATES?
- The company number of EVENS OCULAR ASSOCIATES is 0473.645.654. The VAT number is the same number with BE in front: BE 0473.645.654.
- Where is EVENS OCULAR ASSOCIATES based?
- The registered office is at Kaasmarkt 97, 1780 Wemmel.Company details
- What does EVENS OCULAR ASSOCIATES do?
- According to the KBO register, the main activity is specialist medical practice (NACE 86220).
- What is the legal form of EVENS OCULAR ASSOCIATES?
- EVENS OCULAR ASSOCIATES is a private limited company (BV).
- When was EVENS OCULAR ASSOCIATES founded?
- EVENS OCULAR ASSOCIATES was founded on 29-12-2000.
- Is EVENS OCULAR ASSOCIATES still active?
- Yes, EVENS OCULAR ASSOCIATES is an active enterprise in the KBO register.
- How many employees does EVENS OCULAR ASSOCIATES have?
- EVENS OCULAR ASSOCIATES had an average of 16.4 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
- Which joint committee does EVENS OCULAR ASSOCIATES fall under?
- In its 30-06-2025 annual accounts, EVENS OCULAR ASSOCIATES states joint committee 330 (Health institutions and services).
- What is the turnover of EVENS OCULAR ASSOCIATES?
- The turnover in financial year 2025 is ≈ €2.3m. This figure is estimated from the gross margin of €2.6m and 64 comparable companies (NACE 86). It probably lies between €2.1m and €3.5m.
- Is EVENS OCULAR ASSOCIATES profitable?
- In financial year 2025, EVENS OCULAR ASSOCIATES made a profit of €624,401.
- Where can I find the annual accounts of EVENS OCULAR ASSOCIATES?
- EVENS OCULAR ASSOCIATES filed 24 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of EVENS OCULAR ASSOCIATES due?
- EVENS OCULAR ASSOCIATES must file the annual accounts for financial year 2026 by 31-01-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence See whether the workforce is growing and whether people stay.Employer check Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check See which support similar companies received that this one did not.Subsidies
See how customers, suppliers and banks see your own company and what to improve first.